⌘K
Loading ticker…
Keros Therapeutics, Inc. Common Stock · Healthcare · Pharmaceutical Products
As of 2026-06-26, Keros Therapeutics, Inc. Common Stock (KROS) has a 3-month relative strength percentile of 38 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 42. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 4.8%, relative volume 6.10×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
38 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
KROS is in a stage 4 downtrend, week 4. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -0.2% / -26.0%.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
KROS is held by 3 ETFs as of Mar 2026. Top owner: IWM at 0.01% weight, $8M notional. Top 3 carry $17M.
Top 3 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| IWMiShares Russell 2000 ETF | 0.01% | $8M |
| VTIVanguard Total Stock Market ETF | 0.00% | $7M |
| VXFVanguard Extended Market ETF | 0.00% | $2M |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | KROS Jan avg: 5.30% median: 4.97% win: 50% σ: 30.76% n: 4 2022-04-12 → 2026-05-29 | KROS Feb avg: -2.70% median: -5.97% win: 25% σ: 18.02% n: 4 2022-04-12 → 2026-05-29 | KROS Mar avg: -12.98% median: -13.90% win: 0% σ: 9.62% n: 4 2022-04-12 → 2026-05-29 | KROS Apr avg: 3.29% median: 0.73% win: 60% σ: 23.16% n: 5 2022-04-12 → 2026-05-29 | KROS May avg: -9.21% median: -2.01% win: 40% σ: 17.62% n: 5 2022-04-12 → 2026-05-29 | KROS Jun avg: -10.61% median: -10.85% win: 0% σ: 7.71% n: 4 2022-04-12 → 2026-05-29 (current) | KROS Jul avg: 9.34% median: 8.51% win: 100% σ: 5.04% n: 4 2022-04-12 → 2026-05-29 | KROS Aug avg: -2.32% median: -1.69% win: 50% σ: 12.59% n: 4 2022-04-12 → 2026-05-29 | KROS Sep avg: 7.31% median: 5.19% win: 75% σ: 15.43% n: 4 2022-04-12 → 2026-05-29 | KROS Oct avg: 4.87% median: -1.92% win: 25% σ: 19.77% n: 4 2022-04-12 → 2026-05-29 | KROS Nov avg: 4.91% median: 2.90% win: 50% σ: 7.42% n: 4 2022-04-12 → 2026-05-29 | KROS Dec avg: -7.18% median: 6.41% win: 50% σ: 45.87% n: 4 2022-04-12 → 2026-05-29 |